Entera Bio (ENTX) Competitors $1.80 -0.02 (-0.83%) As of 03/27/2025 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. AVIR, ZYBT, CRVS, MBX, IMMP, PRME, SLRN, ITOS, CDTX, and ACBShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), Prime Medicine (PRME), Acelyrin (SLRN), iTeos Therapeutics (ITOS), Cidara Therapeutics (CDTX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine Acelyrin iTeos Therapeutics Cidara Therapeutics Aurora Cannabis Atea Pharmaceuticals (NASDAQ:AVIR) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Is AVIR or ENTX more profitable? Atea Pharmaceuticals' return on equity of -34.90% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Entera Bio N/A -107.24%-92.29% Which has higher valuation & earnings, AVIR or ENTX? Entera Bio has higher revenue and earnings than Atea Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.51Entera Bio$99K650.64-$8.89M-$0.26-6.92 Does the MarketBeat Community believe in AVIR or ENTX? Entera Bio received 161 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 67.67% of users gave Entera Bio an outperform vote while only 48.72% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1948.72% Underperform Votes2051.28% Entera BioOutperform Votes18067.67% Underperform Votes8632.33% Which has more risk and volatility, AVIR or ENTX? Atea Pharmaceuticals has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Does the media favor AVIR or ENTX? In the previous week, Atea Pharmaceuticals had 4 more articles in the media than Entera Bio. MarketBeat recorded 7 mentions for Atea Pharmaceuticals and 3 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.96 beat Atea Pharmaceuticals' score of 0.18 indicating that Entera Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of AVIR or ENTX? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 17.8% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate AVIR or ENTX? Atea Pharmaceuticals presently has a consensus price target of $6.88, indicating a potential upside of 127.81%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 455.56%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEntera Bio beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Remove Ads Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.41M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-6.9229.2923.1419.03Price / Sales650.64436.17385.7893.17Price / CashN/A168.6838.1634.64Price / Book5.003.956.934.33Net Income-$8.89M-$71.95M$3.20B$247.06M7 Day Performance-7.69%-3.76%-2.30%-0.37%1 Month Performance-2.70%-10.33%2.86%-3.85%1 Year Performance7.78%-27.15%10.66%1.27% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.6659 of 5 stars$1.80-0.8%$10.00+455.6%+16.9%$64.41M$99,000.00-6.9220Upcoming EarningsShort Interest ↓AVIRAtea Pharmaceuticals2.6578 of 5 stars$3.20-0.6%$6.88+115.0%-24.5%$273.68MN/A-1.5570Positive NewsZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals2.3152 of 5 stars$4.25-1.4%$12.38+191.2%+88.3%$273.09MN/A-4.5730Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMBXMBX Biosciences1.529 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036IMMPImmutep1.7616 of 5 stars$1.84-2.1%$8.50+362.0%-23.8%$267.83M$5.14M0.002,021Positive NewsGap DownPRMEPrime Medicine2.8807 of 5 stars$2.03+4.1%$13.38+558.9%-70.4%$266.26M$2.98M-0.99234SLRNAcelyrin3.1823 of 5 stars$2.64-4.0%$9.60+263.6%-60.9%$265.87MN/A-1.07135ITOSiTeos Therapeutics2.7505 of 5 stars$6.89+0.1%$25.75+273.7%-49.1%$263.16M$35M-2.1990Positive NewsCDTXCidara Therapeutics4.4024 of 5 stars$23.63+5.2%$39.14+65.6%+28.1%$258.82M$1.28M-0.9390Short Interest ↑ACBAurora Cannabis0.4301 of 5 stars$4.57+2.5%N/A-2.7%$256.14M$320.81M91.421,340 Remove Ads Related Companies and Tools Related Companies Atea Pharmaceuticals Competitors Zhengye Biotechnology Competitors Corvus Pharmaceuticals Competitors MBX Biosciences Competitors Immutep Competitors Prime Medicine Competitors Acelyrin Competitors iTeos Therapeutics Competitors Cidara Therapeutics Competitors Aurora Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
